NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Set Aside: | No Set aside used |
| Posted Date: | Sep 22, 2026 |
| Due Date: | Sep 21, 2026 |
| Solicitation No: | PCA-NCI-09798 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
- Contract Opportunity Type: Special Notice (Updated)
- Updated Published Date: Sep 22, 2026 10:28 am EDT
- Original Published Date: Sep 15, 2026 12:50 pm EDT
- Updated Response Date: Sep 21, 2026 12:00 pm EDT
- Original Response Date: Sep 21, 2026 12:00 pm EDT
- Inactive Policy: 15 days after response date
- Updated Inactive Date: Oct 06, 2026
- Original Inactive Date: Oct 06, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: AJ11 - GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
-
NAICS Code:
- 541990 - All Other Professional, Scientific, and Technical Services
-
Place of Performance:
Rockville , MD 20850USA
Title: Psomagen, Inc. GEM-X Cell testing (ongoing studies)
This is a Notice of Intent to Sole Source (NOI), not a request for proposal. The National Cancer Institute intends to negotiate on an other-than-full-and-open competition basis with Psomagen, Inc., 1330 Piccard Dr., Suite 103, Rockville, MD 20850-4372 for quality control of submitted single cell samples, generation of sequencing libraries with 10X Chromium GEM-X Single Cell 5p RNA, and expression analysis data of (frozen) clinical xenograft biosamples. The testing is being obtained from Psomagen, Inc. to remain consistent with prior data of ongoing research studies. A critical factor in filling the requirement is the limited viability (no more than 2 hours transport time) of the irreplaceable study biosamples.
While this pre-solicitation does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that Psomagen, Inc. is the owner and developer of the required proprietary testing services currently used by NCI in its ongoing research studies. However, vendors who believe that they can provide the capability required to fully meet the Government's requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact prior to the closing date and time of this notice. Interested parties should clearly address the challenge of integrating with existing Psomagen quality control, sequencing libraries and expression analysis data. Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement by referencing “PCA-NCI-09798.”
The statutory authority for this sole source requirement is 41 U.S.C. 3204(b)(2) as implemented by FAR Overhaul 12.102(a) only one source is available. THIS IS NOT A REQUEST FOR PROPOSAL.
All responsible sources that could provide comparable products may submit a capability statement via email to Christine Biser at:
ChristineBi@mail.nih.gov by 12:00 pm EASTERN Daylight Time, Wednesday, September 24, 2026.
Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Christine Biser at ChristineBi@mail.nih.gov.
- OFFICE OF ACQUISITIONS 31Center Dr. 11A35P
- Bethesda , MD 20892
- USA
- Christine Biser
- ChristineBi@mail.nih.gov
- Sep 22, 2026 10:28 am EDTSpecial Notice (Updated)
- Sep 15, 2026 12:50 pm EDT Special Notice (Original)
Related Document
| Sep 15, 2026 | [Special Notice (Original)] NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis |
See Also
Follow Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier
DEPT OF DEFENSE
Due by 10/23/2026
Follow Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier
DEPT OF DEFENSE
Due by 10/23/2026
Follow Broad Agency Announcement DEVCOM C5ISR RTI Active Contract Opportunity Notice ID W56KGU23RRTID
DEPT OF DEFENSE
Due by 10/31/2027
Follow Generally Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and
DEPT OF DEFENSE
Due by 10/18/2028